Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class III · Low risk Terminated Initiated May 30, 2017 (9 years ago)

BuPROPion HCL Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed Moisture Limits: Product tested out-of-specification for moisture content.

Cause type: Failed specification

A physical or chemical test other than potency, dissolution, impurity or stability failed - pH, viscosity, appearance, tablet integrity, fill volume. A product outside its own specification may not perform as designed, even if the active ingredient is present. All failed specification recalls.

What was recalled

BuPROPion HCL Tablets, USP, 75 mg, packaged as UD 100 tablets (10x10), Rx Only, Mfg by: Sandoz Inc., 508 Carnegie Center, Suite 400, Princeton, NJ 08805, NDC: 63739-706-10

Affected NDC 63739-0706-10

Compare with the code on your package — it is the most precise check available.

Drug: Bupropion Category: Mental Health Medication

Recalling firm
Mckesson Packaging Services
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0928-2017 · FDA notice

Low risk, still worth a check. Class III means the product is unlikely to cause harm but breaks an FDA rule (often labeling). If your lot matches, your pharmacy will normally swap it; there is no need for alarm. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Bupropion recalls

See all

Other recalls by Mckesson Packaging Services

All 2017 recalls
Class III · Low risk

Diltiazem CD

Failed Dissolution Specifications. High dissolution results were obtained during stability testing.

Terminated Dissolution failure Mckesson Packaging Services NDC 63739-284-10 D-0715-2018